National Health (Listed drugs on F1 or F2) Amendment Determination 2015 (No. 1) (PB 6 of 2015) (Cth)

PB 6 of 2015

National Health (Listed drugs on F1 or F2) Amendment Determination 2015 (No. 1)

National Health Act 1953

I, ANDREW RINTOUL, Assistant Secretary (Acting), Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated                23         January 2015

ANDREW RINTOUL

Assistant Secretary (Acting)
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health

Part 1         Preliminary

1. Name of Determination

   (1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2015 (No. 1).

   (2)   This Determination may also be cited as PB 6 of 2015.

2. Commencement

   This Determination commences on 1 February 2015.

3. Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

   Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1             Amendments

(Section 3)

[1]     Schedule 1, after item dealing with Ciclesonide

Omit

Cidofovir

[2]     Schedule 2, after item dealing with Doxorubicin

Omit

Doxorubicin – Peglyated Liposomal

Insert

Doxorubicin – Pegylated Liposomal

[3]     Schedule 2, after item dealing with Duloxetine

Omit

Electrolyte replacement (oral)

Insert

Electrolyte Replacement, Oral

[4]     Schedule 2, after item dealing with Thyroxine

Omit

Ticlopidine